Massachusetts Financial Services Co. MA Has $2.52 Million Stock Holdings in Burning Rock Biotech Limited (NASDAQ:BNR)

Massachusetts Financial Services Co. MA trimmed its stake in shares of Burning Rock Biotech Limited (NASDAQ:BNR) by 90.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 391,200 shares of the company’s stock after selling 3,635,692 shares during the quarter. Massachusetts Financial Services Co. MA owned 3.82% of Burning Rock Biotech worth $2,522,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Kynam Capital Management LP grew its holdings in shares of Burning Rock Biotech by 10.9% in the 1st quarter. Kynam Capital Management LP now owns 9,640,914 shares of the company’s stock worth $7,020,000 after purchasing an additional 946,488 shares during the last quarter. 30.03% of the stock is owned by institutional investors and hedge funds.

Burning Rock Biotech Stock Down 7.2 %

Shares of Burning Rock Biotech stock opened at $3.23 on Monday. The stock has a market capitalization of $33.09 million, a P/E ratio of -0.50 and a beta of 0.15. Burning Rock Biotech Limited has a 12-month low of $2.70 and a 12-month high of $11.70. The company has a 50-day simple moving average of $5.82 and a 200 day simple moving average of $6.84.

Burning Rock Biotech (NASDAQ:BNR) last posted its earnings results on Thursday, August 22nd. The company reported ($0.14) earnings per share (EPS) for the quarter. The firm had revenue of $18.65 million during the quarter. Burning Rock Biotech had a negative net margin of 111.25% and a negative return on equity of 72.31%.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.